EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase II)

Effect of neoadjuvant chemoradiotherapy with or without PD-1 antibody sintilimab in pMMR locally advanced rectal cancer: A randomized clinical trial

Wei-Wei Xiao, Gong Chen, Yuan-Hong Gao, Jun-Zhong Lin, Xiao-Jun Wu, Hui-Long Luo, Zhen-Hai Lu, Qiao-Xuan Wang, Rui Sun, Pei-Qiang Cai, Chong-Mei Zhu, Min Liu und 8 weitere

Cancer Cell · 2024-09 · 42 (9) · 1570-1581.e4

DOI: 10.1016/j.ccell.2024.07.004 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Cancer Cell, 2024-09. Verfasst von Wei-Wei Xiao und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Sun Yat-sen University Cancer Center, The State Key Laboratory of Oncology in South China, Guangdong Provincial Cli…. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Chemoradiotherapy, DNA Mismatch Repair, Neoadjuvant Therapy. Die Arbeit wurde bisher 104-mal zitiert (Crossref) und nennt 71 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Innovent Biologics, AstraZeneca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Neoadjuvant chemoradiotherapy (NACRT) was the standard treatment for patients with locally advanced rectal cancer (LARC) with proficient mismatch repair (pMMR) proteins. In this randomized phase 2 trial (ClinicalTrial.gov: NCT04304209), 134 pMMR LARC patients were randomly (1:1) assigned to receive NACRT or NACRT and the programmed cell death protein 1 (PD-1) antibody sintilimab. As the primary endpoint, the total complete response (CR) rate is 26.9% (18/67, 95% confidence interval [CI] 16.0%-37.8%) and 44.8% (30/67, 95% CI 32.6%-57.0%) in the control and experimental arm, respectively, with significant difference (p = 0.031 for chi-squared test). Response ratio is 1.667 (95% CI 1.035-2.683). Immunohistochemistry shows PD-1 ligand 1 (PD-L1) combined positive score is associated with the synergistic effect. The safety profile is similar between the arms. Adding the PD-1 antibody sintilimab to NACRT significantly increases the CR rate in pMMR LARC, with a manageable safety profile. PD-L1 positivity may help identify patients who might benefit most from the combination therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedChemoradiotherapyDNA Mismatch RepairNeoadjuvant TherapyProgrammed Cell Death 1 ReceptorRectal NeoplasmsAdultAgedFemaleHumansMaleMiddle AgedAntineoplastic Combined Chemotherapy ProtocolsImmune Checkpoint InhibitorsNeoplasm Staging

Stichwörter der Autor:innen

PD-1 antibodycombined positive scorecomplete responselocally advanced rectal cancerneoadjuvant chemoradiotherapyproficient mismatch repair

Substanzen

Antibodies, Monoclonal, HumanizedImmune Checkpoint InhibitorsPDCD1 protein, humanProgrammed Cell Death 1 Receptorsintilimab

Autor:innen und Institutionen

  • Department of Radiation Oncology, Sun Yat-sen University Cancer Center, The State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, China; United Laboratory…
  • Department of Colorectal Surgery, Sun Yat-sen University Cancer Center, The State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, China.
  • Department of Radiation Oncology, Sun Yat-sen University Cancer Center, The State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, China.
  • Department of Radiology, Sun Yat-sen University Cancer Center, The State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, China.
  • Department of Pathology, Sun Yat-sen University Cancer Center, The State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, China.
  • Department of Ultrasound, Sun Yat-sen University Cancer Center, The State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, China.

Förderung

  • National Natural Science Foundation of China
  • Innovent Biologics
  • AstraZeneca
  • CAMS Innovation Fund for Medical Sciences
  • Chinese Academy of Meteorological Sciences
  • Cancer Research Foundation

Zitieren

APA

Xiao, W. W., Chen, G., Gao, Y. H., Lin, J. Z., Wu, X. J., Luo, H. L., Lu, Z. H., Wang, Q. X., Sun, R., Cai, P. Q., Zhu, C. M., Liu, M., Li, J. B., Wang, Y. R., Jin, Y., Wang, F., Luo, H. T., Li, C. L., Pan, Z. Z., & Xu, R. H. (2024). Effect of neoadjuvant chemoradiotherapy with or without PD-1 antibody sintilimab in pMMR locally advanced rectal cancer: A randomized clinical trial. Cancer Cell, 42(9), 1570-1581.e4. https://doi.org/10.1016/j.ccell.2024.07.004

Vancouver

Xiao WW, Chen G, Gao YH, Lin JZ, Wu XJ, Luo HL, et al. Effect of neoadjuvant chemoradiotherapy with or without PD-1 antibody sintilimab in pMMR locally advanced rectal cancer: A randomized clinical trial. Cancer Cell. 2024;42(9):1570-1581.e4. doi:10.1016/j.ccell.2024.07.004

BibTeX
@article{Xiao2024,
  author = {Xiao, Wei-Wei and Chen, Gong and Gao, Yuan-Hong and Lin, Jun-Zhong and Wu, Xiao-Jun and Luo, Hui-Long and Lu, Zhen-Hai and Wang, Qiao-Xuan and Sun, Rui and Cai, Pei-Qiang and Zhu, Chong-Mei and Liu, Min and Li, Ji-Bin and Wang, Yi-Rui and Jin, Ying and Wang, Feng and Luo, Hai-Tao and Li, Cai-Ling and Pan, Zhi-Zhong and Xu, Rui-Hua},
  title = {Effect of neoadjuvant chemoradiotherapy with or without PD-1 antibody sintilimab in pMMR locally advanced rectal cancer: A randomized clinical trial},
  journal = {Cancer Cell},
  year = {2024},
  volume = {42},
  number = {9},
  pages = {1570--1581.e4},
  doi = {10.1016/j.ccell.2024.07.004}
}
Kostenlos starten →